PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34638732-8 2021 The results confirmed the elevation of AMPK and mitochondrial respiratory activities and reduction in reactive O2 species (ROS) levels in premutation cells and revealed for the first time that target of rapamycin complex I (TORC1) activities are reduced. Sirolimus 203-212 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 39-43 33227845-1 2020 Background: Sestrin2 (Sesn2) is involved in the maintenance of metabolic homeostasis and aging via modulation of the 5" AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) pathway. Sirolimus 169-178 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 180-184 34703880-6 2021 Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT. Sirolimus 185-194 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 129-157 34703880-6 2021 Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT. Sirolimus 185-194 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 159-163 34590575-5 2021 Fatty acids and glucose metabolites are involved in regulation of immune response mainly via free fatty acid receptors and AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. Sirolimus 172-181 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 183-187 34646153-5 2021 This prioritization/interference may be due to the interplay between the 5" AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling cascades and/or the high skeletal muscle energy requirements for the synthesis and maintenance of cellular organelles. Sirolimus 138-147 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 76-104 34646153-5 2021 This prioritization/interference may be due to the interplay between the 5" AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling cascades and/or the high skeletal muscle energy requirements for the synthesis and maintenance of cellular organelles. Sirolimus 138-147 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 106-110 35368869-4 2022 While both MD and AA+MD increased phosphorylation of AMP-activated protein kinase (AMPK), the well-known autophagy promotor, only the combined treatment affected its downstream targets, mechanistic target of rapamycin complex 1 (mTORC1), Unc 51-like kinase 1 (ULK1), and increased the expression of several autophagy-related genes. Sirolimus 208-217 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 53-81 35368869-4 2022 While both MD and AA+MD increased phosphorylation of AMP-activated protein kinase (AMPK), the well-known autophagy promotor, only the combined treatment affected its downstream targets, mechanistic target of rapamycin complex 1 (mTORC1), Unc 51-like kinase 1 (ULK1), and increased the expression of several autophagy-related genes. Sirolimus 208-217 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 83-87 33613450-4 2020 This study aimed to investigate the effect of 17beta-E2 on Sirtuin-1 (SIRT1) expression and the induction of mitophagy upregulation by 17beta-E2 via the SIRT1-mediated AMP-activated protein kinase (AMPK)/mammalian target of the rapamycin (mTOR) signaling pathway to protect chondrocytes. Sirolimus 228-237 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 168-196 32395371-2 2020 Sesn2 regulates cellular metabolism by inhibiting the mammalian target of rapamycin complex 1 through the AMP-activated protein kinase (AMPK) signaling pathway. Sirolimus 74-83 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 106-134 32599128-7 2020 Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells. Sirolimus 0-9 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 69-73 32599128-8 2020 Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs. Sirolimus 45-54 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 152-156 32765221-13 2020 Furthermore, BMSC-Exos promoted autophagic flux through the AMP-activated kinase (AMPK)/mammalian target of the rapamycin pathway, whereas chloroquine, AMPK silencing, and compound C blocked the inhibitory effect on pyroptosis. Sirolimus 112-121 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 60-80 32765221-13 2020 Furthermore, BMSC-Exos promoted autophagic flux through the AMP-activated kinase (AMPK)/mammalian target of the rapamycin pathway, whereas chloroquine, AMPK silencing, and compound C blocked the inhibitory effect on pyroptosis. Sirolimus 112-121 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 82-86 32516310-1 2020 Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions. Sirolimus 174-183 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 207-235 32516310-1 2020 Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions. Sirolimus 174-183 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 237-241 32898934-1 2020 Ginsenoside Rg3, a ginsenoside isolated from Panax ginseng, can regulate autophagy via AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. Sirolimus 136-145 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 147-151 31943518-2 2020 This study aimed to investigate the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway in sepsis-induced leucine resistance and its upstream signals, and to seek a way to correct leucine resistance in sepsis. Sirolimus 85-94 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 96-100 32395371-2 2020 Sesn2 regulates cellular metabolism by inhibiting the mammalian target of rapamycin complex 1 through the AMP-activated protein kinase (AMPK) signaling pathway. Sirolimus 74-83 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 136-140 31173176-8 2019 A prospective mechanism for the function of CUR NPs is that they may activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex-1/p-p70 ribosomal protein S6 kinase signaling pathway, regulate the expression of downstream proteins and resist the palmitate-induced cardiomyocyte injury. Sirolimus 138-147 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 82-110 31314175-5 2019 This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex. Sirolimus 218-227 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 22-50 31314175-5 2019 This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex. Sirolimus 218-227 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 52-56 31417118-7 2019 The study indicated that the sequential regulation of AMPK-mammalian target of rapamycin complex 1-eEF2 signaling was altered and protein synthesis ability was reduced in the cerebral cortex of hibernating chipmunks. Sirolimus 79-88 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 54-58 31173176-8 2019 A prospective mechanism for the function of CUR NPs is that they may activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex-1/p-p70 ribosomal protein S6 kinase signaling pathway, regulate the expression of downstream proteins and resist the palmitate-induced cardiomyocyte injury. Sirolimus 138-147 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 112-116 30445633-10 2019 Taken together, our study demonstrated that metformin suppressed the carcinogenesis of ESCC through inhibiting AMPK/mammalian target of the rapamycin (mTOR) signaling pathway, resulting in its chemopreventive effects on the carcinogenesis of ESCC. Sirolimus 140-149 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 111-115 31033201-3 2019 The agent also stimulates AMP-activated protein kinase (AMPK) and consequently influences the mammalian target of rapamycin complex 1 (mTORC1) pathways. Sirolimus 114-123 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 26-54 31033201-3 2019 The agent also stimulates AMP-activated protein kinase (AMPK) and consequently influences the mammalian target of rapamycin complex 1 (mTORC1) pathways. Sirolimus 114-123 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 56-60 21871960-9 2012 Mevalonate, the product of HMG-CoA reductase enzymatic activity, AMPK siRNA or pharmacological inactivation of AMPK with compound C suppressed, while the inhibitors of Akt (10-DEBC hydrochloride) and mTOR (rapamycin) mimicked autophagy induction by simvastatin. Sirolimus 206-215 protein kinase AMP-activated non-catalytic subunit beta 1 Homo sapiens 111-115